|
1
|
Greene JM, Schneble EJ, Jackson DO, Hale
DF, Vreeland TJ, Flores M, Martin J, Herbert GS, Hardin MO, Yu X,
et al: A phase I/IIa clinical trial in stage IV melanoma of an
autologous tumor-dendritic cell fusion (dendritoma) vaccine with
low dose interleukin-2. Cancer Immunol Immunother. 65:383–392.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ong CC, Jubb AM, Jakubiak D, Zhou W,
Rudolph J, Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle R, et
al: P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF
wild-type melanoma. J Natl Cancer Inst. 105:606–607. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Benyi E, Kieler H, Linder M, Ritzén M,
Carlstedt-Duke J, Tuvemo T, Westphal O and Sävendahl L: Risks of
malignant and non-malignant tumours in tall women treated with
high-dose oestrogen during adolescence. Horm Res Paediatr.
82:89–96. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eggermont AM, Suciu S, Rutkowski P, Kruit
WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G and
Testori A: EORTC Melanoma Group: Long term follow up of the EORTC
18952 trial of adjuvant therapy in resected stage IIB-III cutaneous
melanoma patients comparing intermediate doses of
interferon-alpha-2b (IFN) with observation: Ulceration of primary
is key determinant for IFN-sensitivity. Eur J Cancer. 55:111–121.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Varamo C, Occelli M, Vivenza D, Merlano M
and Lo Nigro C: MicroRNAs role as potential biomarkers and key
regulators in melanoma. Genes Chromosomes Cancer. 56:3–10. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Babapoor S, Horwich M, Wu R, Levinson S,
Gandhi M, Makkar H, Kristjansson A, Chang M and Dadras SS: microRNA
in situ hybridization for miR-211 detection as an ancillary test in
melanoma diagnosis. Mod Pathol. 29:461–475. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Venkatesan N, Kanwar J, Deepa PR, Khetan
V, Crowley TM, Raguraman R, Sugneswari G, Rishi P, Natarajan V,
Biswas J, et al: Clinico-pathological association of delineated
miRNAs in uveal melanoma with monosomy 3/disomy 3 chromosomal
aberrations. PLoS One. 11:e01461282016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dror S, Sander L, Schwartz H, Sheinboim D,
Barzilai A, Dishon Y, Apcher S, Golan T, Greenberger S, Barshack I,
et al: Melanoma miRNA trafficking controls tumour primary niche
formation. Nat Cell Biol. 18:1006–1017. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kou Y, Li L, Li H, Tan Y, Li B, Wang K and
Du B: Berberine suppressed epithelial mesenchymal transition
through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma
cells. Biochem Biophys Res Commun. 479:290–296. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu G, Zhang W, Bertram P, Zheng XF and
McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR
pathway in common human tumors. Int J Oncol. 24:893–900.
2004.PubMed/NCBI
|
|
11
|
Dong MH, Zhang Q, Wang YY, Zhou BS, Sun YF
and Fu Q: Euphorbia fischeriana Steud inhibits malignant melanoma
via modulation of the phosphoinositide-3-kinase/Akt signaling
pathway. Exp Ther Med. 11:1475–1480. 2016.PubMed/NCBI
|
|
12
|
Doscas ME, Williamson AJ, Usha L,
Bogachkov Y, Rao GS, Xiao F, Wang Y, Ruby C, Kaufman H, Zhou J, et
al: Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its
effect on cell proliferation and cell cycle progress. Neoplasia.
16:824–834. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo Y, Chang H, Li J, Xu XY, Shen L, Yu ZB
and Liu WC: Thymosin alpha 1 suppresses proliferation and induces
apoptosis in breast cancer cells through PTEN-mediated inhibition
of PI3K/Akt/mTOR signaling pathway. Apoptosis. 20:1109–1121. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guterres FA, Martinez GR, Rocha ME and
Winnischofer SM: Simvastatin rises reactive oxygen species levels
and induces senescence in human melanoma cells by activation of
p53/p21 pathway. Exp Cell Res. 319:2977–2988. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Andrade BA, León JE, Carlos R,
Delgado-Azañero W, Mosqueda-Taylor A and de Almeida OP:
Immunohistochemical expression of p16, p21, p27 and cyclin D1 in
oral nevi and melanoma. Head Neck Pathol. 6:297–304. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jang GH and Lee M: BH3-mimetic
gossypol-induced autophagic cell death in mutant BRAF melanoma
cells with high expression of p21Cip¹). Life Sci. 102:41–48. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van der Ploeg AP, Haydu LE, Spillane AJ,
Scolyer RA, Quinn MJ, Saw RP, Shannon KF, Stretch JR and Thompson
JF: Melanoma patients with an unknown primary tumor site have a
better outcome than those with a known primary following
therapeutic lymph node dissection for macroscopic (clinically
palpable) nodal disease. Ann Surg Oncol. 21:3108–3116. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
18. Plimack ER, Desai JR, Issa JP, Jelinek
J, Sharma P, Vence LM, Bassett RL, Ilagan JL, Papadopoulos NE and
Hwu WJ: A phase I study of decitabine with pegylated interferon
α-2b in advanced melanoma: Impact on DNA methylation and lymphocyte
populations. Invest New Drugs. 32:969–975. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
19. Robert C, Dummer R, Gutzmer R, Lorigan
P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini
M, et al: Selumetinib plus dacarbazine versus placebo plus
dacarbazine as first-line treatment for BRAF-mutant metastatic
melanoma: A phase 2 double-blind randomised study. Lancet Oncol.
14:733–740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
20. Wang K, Gao W, Dou Q, Li Q, Nice EC
and Huang C: Ivermectin induces PAK1-mediated cytostatic autophagy
in breast cancer. Autophagy. 12:2498–2499. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
21. Vucicevic L, Misirkic M, Janjetovic K,
Vilimanovich U, Sudar E, Isenovic E, Prica M, Harhaji-Trajkovic L,
Kravic-Stevovic T, Bumbasirevic V, et al: Compound C induces
protective autophagy in cancer cells through AMPK
inhibition-independent blockade of Akt/mTOR pathway. Autophagy.
7:40–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
22. Syed DN, Chamcheu JC, Khan MI, Sechi
M, Lall RK, Adhami VM and Mukhtar H: Fisetin inhibits human
melanoma cell growth through direct binding to p70S6K and mTOR:
Findings from 3-D melanoma skin equivalents and computational
modeling. Biochem Pharmacol. 89:349–360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
23. Babchia N, Calipel A, Mouriaux F,
Faussat AM and Mascarelli F: The PI3K/Akt and mTOR/P70S6K signaling
pathways in human uveal melanoma cells: Interaction with B-Raf/ERK.
Invest Ophthalmol Vis Sci. 51:421–429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
24. Caporali S, Alvino E, Lacal PM, Levati
L, Giurato G, Memoli D, Caprini E, Cappellini Antonini GC and
D'Atri S: Targeting the PI3K/AKT/mTOR pathway overcomes the
stimulating effect of dabrafenib on the invasive behavior of
melanoma cells with acquired resistance to the BRAF inhibitor. Int
J Oncol. 49:1164–1174. 2016.PubMed/NCBI
|
|
25
|
25. Pappalardo F, Russo G, Candido S,
Pennisi M, Cavalieri S, Motta S, McCubrey JA, Nicoletti F and Libra
M: Computational modeling of PI3K/AKT and MAPK signaling pathways
in melanoma cancer. PLoS One. 11:e01521042016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
26. Chi H: miR-194 regulated AGK and
inhibited cell proliferation of oral squamous cell carcinoma by
reducing PI3K-Akt-FoxO3a signaling. Biomed Pharmacother. 71:53–57.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
27. Krützfeldt J, Rösch N, Hausser J,
Manoharan M, Zavolan M and Stoffel M: MicroRNA-194 is a target of
transcription factor 1 (Tcf1, HNF1α) in adult liver and controls
expression of frizzled-6. Hepatology. 55:98–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
28. Lawrence NF, Hammond MR, Frederick DT,
Su Y, Dias-Santagata D, Deng A, Selim MA, Mahalingam M, Flaherty KT
and Hoang MP: Ki-67, p53, and p16 expression, and G691S RET
polymorphism in desmoplastic melanoma (DM): A clinicopathologic
analysis of predictors of outcome. J Am Acad Dermatol. 75:595–602.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
29. Perrotta C, Buonanno F, Zecchini S,
Giavazzi A, Serafini Proietti F, Catalani E, Guerra L, Belardinelli
MC, Picchietti S, Fausto AM, et al: Climacostol reduces tumour
progression in a mouse model of melanoma via the p53-dependent
intrinsic apoptotic programme. Sci Rep. 6:272812016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
30. Zhao S, Niu F, Xu CY, Ye L, Bi GB,
Chen L, Gong P, Tian G and Nie TH: Microarray and ChIP-seq data
analysis revealed changes in p53-mediated transcriptional
regulation in Nutlin-3-treated U2OS cells. Mol Med Rep.
12:4284–4290. 2015.PubMed/NCBI
|
|
31
|
31. Kaluzki I, Hrgovic I, Hailemariam-Jahn
T, Doll M, Kleemann J, Valesky EM, Kippenberger S, Kaufmann R,
Zoeller N and Meissner M: Dimethylfumarate inhibits melanoma cell
proliferation via p21 and p53 induction and bcl-2 and cyclin B1
downregulation. Tumour Biol. 37:13627–13635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
32. Fan T, Jiang S, Chung N, Alikhan A, Ni
C, Lee CC and Hornyak TJ: EZH2-dependent suppression of a cellular
senescence phenotype in melanoma cells by inhibition of p21/CDKN1A
expression. Mol Cancer Res. 9:418–429. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
33. Genov M, Kreiseder B, Nagl M, Drucker
E, Wiederstein M, Muellauer B, Krebs J, Grohmann T, Pretsch D,
Baumann K, et al: Tetrahydroanthraquinone derivative
(±)-4-deoxyaustrocortilutein induces cell cycle arrest and
apoptosis in melanoma cells via upregulation of p21 and p53 and
downregulation of NF-kappaB. J Cancer. 7:555–568. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
34. Yun CY, You ST, Kim JH, Chung JH, Han
SB, Shin EY and Kim EG: p21-activated kinase 4 critically regulates
melanogenesis via activation of the CREB/MITF and β-catenin/MITF
pathways. J Invest Dermatol. 135:1385–1394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
35. Pelletier J, Dayan F, Durivault J, Ilc
K, Pécou E, Pouysségur J and Mazure NM: The asparaginyl hydroxylase
factor-inhibiting HIF is essential for tumor growth through
suppression of the p53-p21 axis. Oncogene. 31:2989–3001. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
36. Nicolau-Galmés F, Asumendi A,
Alonso-Tejerina E, Pérez-Yarza G, Jangi SM, Gardeazabal J,
Arroyo-Berdugo Y, Careaga JM, Díaz-Ramón JL, Apraiz A, et al:
Terfenadine induces apoptosis and autophagy in melanoma cells
through ROS-dependent and -independent mechanisms. Apoptosis.
16:1253–1267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
37. Sundaram P, Hultine S, Smith LM, Dews
M, Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV,
et al: p53-responsive miR-194 inhibits thrombospondin-1 and
promotes angiogenesis in colon cancers. Cancer Res. 71:7490–7501.
2011. View Article : Google Scholar : PubMed/NCBI
|
